Equities analysts forecast that Johnson & Johnson (NYSE:JNJ) will post sales of $20.40 billion for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for Johnson & Johnson’s earnings, with estimates ranging from $20.28 billion to $20.53 billion. Johnson & Johnson reported sales of $20.73 billion in the same quarter last year, which would suggest a negative year-over-year growth rate of 1.6%. The company is scheduled to announce its next earnings report before the market opens on Tuesday, October 13th.
On average, analysts expect that Johnson & Johnson will report full-year sales of $80.86 billion for the current financial year, with estimates ranging from $80.43 billion to $81.26 billion. For the next fiscal year, analysts forecast that the business will report sales of $87.73 billion, with estimates ranging from $86.42 billion to $88.93 billion. Zacks’ sales averages are an average based on a survey of sell-side research firms that cover Johnson & Johnson.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Thursday, July 16th. The company reported $1.67 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.50 by $0.17. Johnson & Johnson had a return on equity of 35.21% and a net margin of 22.69%. The firm had revenue of $18.34 billion during the quarter, compared to the consensus estimate of $17.73 billion. During the same quarter in the previous year, the business earned $2.58 earnings per share. The firm’s quarterly revenue was down 10.8% compared to the same quarter last year.
JNJ has been the subject of a number of research reports. Raymond James boosted their price target on Johnson & Johnson from $157.00 to $158.00 and gave the company an “outperform” rating in a research report on Friday, July 17th. Cantor Fitzgerald restated a “buy” rating and set a $168.00 price objective on shares of Johnson & Johnson in a research note on Monday, August 3rd. Credit Suisse Group restated a “buy” rating on shares of Johnson & Johnson in a research note on Friday, September 4th. Bank of America restated a “buy” rating on shares of Johnson & Johnson in a research note on Monday, July 20th. Finally, SVB Leerink restated an “outperform” rating on shares of Johnson & Johnson in a research note on Wednesday, July 15th. One analyst has rated the stock with a sell rating, five have given a hold rating and eleven have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $163.00.
In related news, EVP Kathryn E. Wengel sold 16,115 shares of the business’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $153.52, for a total value of $2,473,974.80. Following the transaction, the executive vice president now owns 66,658 shares in the company, valued at $10,233,336.16. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Ashley Mcevoy sold 29,000 shares of the business’s stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $147.47, for a total value of $4,276,630.00. Following the completion of the transaction, the executive vice president now owns 21,682 shares in the company, valued at approximately $3,197,444.54. The disclosure for this sale can be found here. Insiders own 0.27% of the company’s stock.
Several large investors have recently added to or reduced their stakes in the stock. Tradewinds Capital Management LLC raised its stake in Johnson & Johnson by 1.3% during the first quarter. Tradewinds Capital Management LLC now owns 7,602 shares of the company’s stock valued at $997,000 after buying an additional 101 shares in the last quarter. Dempze Nancy E raised its stake in Johnson & Johnson by 0.4% during the second quarter. Dempze Nancy E now owns 20,907 shares of the company’s stock valued at $2,939,000 after buying an additional 80 shares in the last quarter. Bessemer Group Inc. raised its stake in Johnson & Johnson by 10.3% during the second quarter. Bessemer Group Inc. now owns 268,577 shares of the company’s stock valued at $37,769,000 after buying an additional 25,097 shares in the last quarter. Private Asset Management Inc. raised its stake in Johnson & Johnson by 0.5% during the second quarter. Private Asset Management Inc. now owns 93,956 shares of the company’s stock valued at $13,213,000 after buying an additional 425 shares in the last quarter. Finally, Martin Investment Management LLC raised its stake in Johnson & Johnson by 5.1% during the second quarter. Martin Investment Management LLC now owns 32,745 shares of the company’s stock valued at $4,605,000 after buying an additional 1,586 shares in the last quarter. Institutional investors and hedge funds own 67.44% of the company’s stock.
JNJ stock traded down $1.08 during trading on Wednesday, reaching $146.24. 5,485,602 shares of the stock traded hands, compared to its average volume of 8,360,347. The business’s 50 day moving average price is $149.19 and its 200-day moving average price is $144.96. Johnson & Johnson has a 52-week low of $109.16 and a 52-week high of $157.00. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.25 and a quick ratio of 0.99. The firm has a market capitalization of $385.02 billion, a PE ratio of 21.38, a P/E/G ratio of 3.29 and a beta of 0.68.
The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 8th. Investors of record on Tuesday, August 25th were paid a $1.01 dividend. This represents a $4.04 annualized dividend and a dividend yield of 2.76%. The ex-dividend date was Monday, August 24th. Johnson & Johnson’s dividend payout ratio (DPR) is 46.54%.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Read More: What is a Buy-Side Analyst?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.